Results 171 to 180 of about 32,631 (259)

ScarNet: a novel foundation model for automated myocardial scar quantification from late gadolinium-enhancement images. [PDF]

J Cardiovasc Magn Reson
Tavakoli N, Rahsepar AA, Benefield BC, Shen D, López-Tapia S, Schiffers F, Goldberger JJ, Albert CM, Wu E, Katsaggelos AK, Lee DC, Kim D.   +11 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Papillary muscle infarction detection: unveiling the unseen with dual bright- and black-blood late gadolinium enhancement SPOT imaging. [PDF]

Eur Heart J Imaging Methods Pract
Richard T, de Villedon de Naide V, Narceau K, Génisson T, He K, Boullé T, Poirot G, Sridi S, Jaïs P, Stuber M, Cochet H, Bustin A.   +11 more
europepmc   +1 more source

Predictors of late gadolinium enhancement cardiac MRI image quality in patients with cardiac implantable electronic devices. [PDF]

Heart Rhythm O2
Amrani F, Hopman LHGA, Postema PG, Kemme MJB, Allaart CP, Selder JL, van Loon RB, van Halm VP, Götte MJW, Bhagirath P.   +9 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

The Prognostic Implication of Late Gadolinium Enhancement Quantification and Syncope in Hypertrophic Cardiomyopathy. [PDF]

J Clin Med
Mann C, Dachs TM, Gharib D, Widmann K, Tosun R, Srdits M, Kronberger C, Beitzke D, Loewe C, Kammerlander AA, Gwechenberger M, Lang IM, Hengstenberg C, Zelniker TA, Dalos D.   +14 more
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Variant-Specific Late Gadolinium Enhancement Patterns Influence Clinical Outcomes in <i>LMNA</i>-Related Cardiomyopathy. [PDF]

J Am Heart Assoc
Castrichini M, Garmany R, Siontis KC, Collins JD, Bois JP, Pereira NL, Tester DJ, Gluscevic M, Huynh T, Neves R, Rosenbaum AN, Ackerman MJ, Giudicessi JR.   +12 more
europepmc   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Wideband black- and bright-blood late gadolinium enhancement imaging in patients with implantable cardiac devices at 1.5 T for improved visualization and localization of myocardial injury. [PDF]

Eur Heart J Imaging Methods Pract
Gut P, Cochet H, Caluori G, Vlachos K, Antiochos P, Durand B, Masi A, Schwitter J, Sacher F, Jaïs P, Stuber M, Bustin A.   +11 more
europepmc   +1 more source